EUCTR2010-022757-42-GB进行中（未招募）1 期
A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Histologically and/or cytologically confirmed inoperable ductal adenocarcinoma of the pancreas, including the mucinous variant. This will include locally advanced and metastatic disease (stage III/IV).
- •Presence of measurable lesions in at least one site which have not been previously irradiated (bone lesions, ascites and pleural effusions are not considered as measurable), described as any of the following:
- •Any primary tumour with at least bi-dimensionally measurable disease.
- •a) Palpable lymph nodes, b) Deep seated lymph nodes.
- •Liver metastases measurable by computerised tomography (CT) scan.
- •Deep seated soft tissue lesions measurable by CT scan.
- •WHO performance status of 0-2.
- •Serum creatinine <140 µmol/L.
- •White blood cell (WBC) count, including differential counts within the normal range or, if outside the normal range, considered by the investigator to be not clinically significant.
- •Life expectancy, in the opinion of the Investigator, of >3 months from randomisation.
- •Provide written informed consent to participate as shown by a signature and date on the patient's informed consent form (ICF)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Patients will be ineligible if one or more of the following statements are applicable:
- •Patient has acinar cell carcinoma, neuroendocrine tumours, lymphomas or squamous cell carcinomas.
- •Patient has severe, active uncontrolled infection requiring systemic antibiotics, antiviral or antifungal treatments.
- •Patient has been on any previous chemotherapy treatment for pancreatic cancer.
- •Patient is eligible for resection of the pancreatic primary tumour but has either refused the operation or is considered to be medically unfit for the operation.
- •Patient has clinical or CT evidence of central nervous system (CNS) metastases.
- •Patient has any previous or concurrent malignancy, except adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin and/or non-melanoma skin cancer, or if previous malignancy was more than 5 years prior and there are no signs of recurrence.
- •Patient has serum albumin < 26 g/L.
- •Patient has a C-reactive protein (CRP) > 70 mg/L.
- •Patient has had radiotherapy in the 6 weeks prior to screening.
- •Patient has used depot corticosteroids in the 6 weeks prior to screening.
- •Patient has had chronic use of any systemic corticosteroids (>10 mg per day of prednisolone or equivalent for a period of 2 weeks or more) and/or immunosuppressant drugs (such as azathioprine, tacrolimus, cyclosporin) within the 2-week period prior to the first administration of study drug.
- •Female patient of child-bearing potential who is not, in the opinion of the Investigator, using an approved method of birth control (e.g. physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]). Those patients that utilise hormonal contraceptives must have used the same method for at least three months before study dosing. Patient of non-child-bearing potential are defined as having 12 month amenorrhoea or are surgically sterile.
- •Female patient who is pregnant, breast feeding or planning a pregnancy during the course of the study. A pre-treatment serum pregnancy test measuring human chorionic gonadotrophin (HCG) must be negative.
- •Patient has been administered any investigational drug, vaccine or device in the 3 months prior to screening. Patient has a surgical or medical condition which, in the judgement of the Investigator, might interfere with the activity of IMM-101, or with the performance of this study.
- •Patient has presence of any uncontrolled concomitant disease (e.g. unstable angina pectoris, congestive heart failure, myocardial infarction, arrhythmias, uncontrolled severe hypertension) which, in the judgement of the Investigator, might interfere with the activity of IMM-101, or with the performance of this study.
- •Patient has a history of serious adverse reaction or serious hypersensitivity to any drug.
- •Patient has had any previous treatment with IMM-101 or related mycobacterial immunotherapy.
- •Patient is known to have a history of human immunodeficiency virus (HIV) or syphilis, current symptomatic Hepatitis B or C. Testing is not required in the absence of clinical signs and symptoms suggestive of infection with HIV.
- •Patient is unable or unwilling
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study Comparing the effects of Gemcitabine with and without IMM-101 in Advanced Pancreatic CancerAdvanced pancreatic cancer. The overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and tolerability, QoL, clinical signs and symptoms of disease, disease outcome and selected markers of tumour burden and immunological status in patients with inoperable, locally advanced or metastatic pancreatic cancer.MedDRA version: 14.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022757-42-ITIMMODULON THERAPEUTICS LTD80
进行中（未招募）
不适用
A Phase II Study Comparing the effects of Gemcitabine with and without IMM-101 in Advanced Pancreatic CancerAdvanced pancreatic cancerThe overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and tolerability, QoL, clinical signs and symptoms of disease, disease outcome and selected markers of tumour burden and immunological status in patients with inoperable, locally advanced or metastatic pancreatic cancer.MedDRA version: 14.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022757-42-IEImmodulon Therapeutics Limited80
进行中（未招募）
1 期
A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic CancerEnsayo Clínico Fase 2, Randomizado, Abierto, Prueba de Concepto para comparar Gemcitabina con y sin IMM-101 en Cancer Pancreatico AvanzadoCáncer pancreático avanzado: El objetivo global the este estudio clinico es evaluar la sinergia potencial entre Gemcitabina y IMM-101 y cualquier efecto beneficial que esto pueda tener en la seguridad y tolerabilidad, calidad de vida, signos clinicos y sintomas de la enfermedad, resultado de la enfermedad y marcadores seleccionados de masa tujora y estado immunológico en pacientes con cancer pancreatico locamente avanzado inoperable o con metastasisMedDRA version: 14.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022757-42-ESImmodulon Therapeutics Limited80
招募中
4 期
A computerized visual training study for visual stimulation in Patients Suffering from Keratoconus.CTRI/2022/09/045779one
招募中
4 期
A computerized visual training study for visual stimulation in cataract patients following diffractive Intra Ocular lens Implantation.CTRI/2022/08/045110one